In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of donor HCV nucleic-acid testing positive (HCV NAT+) cardiac transplantation
Timeframe: 6.5 years
Failure versus Cure Rate for HCV NAT+ Heart Transplants
Timeframe: 6.5 years
Rate of Primary graft dysfunction (PGD)
Timeframe: 30 days
1 year mortality
Timeframe: 1 Year
Cellular graft rejection rate
Timeframe: 6.5 years
Antibody Mediated Rejection rate
Timeframe: 6.5 years